PneumoconiosisPANDECTNCT07077382
Pneumoconiosis and Dust Exposure China Cohort
An observational study of Pneumoconiosis, run by China-Japan Friendship Hospital at 1 site in China.
Trial summary
The primary objective of this study is to characterize the demographic and clinical features of patients with occupational pneumoconiosis (hereinafter referred to as pneumoconiosis) in China. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Pneumoconiosis
- How many people
- 2,000 participants
- Where
- 1 siteChina
- Study dates
- 28 May 2021to 31 May 2030
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Patients were selected during physical examinations or during hospitalization from medical organization.
Who may be able to join
- Diagnosed as pneumoconiosis
Who cannot join
- Incomplete occupational history information
- Has participated in any interventional clinical research
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
China-Japan Friendship Hospital
Beijing, Beijing Municipality, 100029
Huaping Dai, M.D. Ph.D., 0086-010-84206271, daihuaping@sina.com
About this study
The primary objective of this study is to characterize the demographic and clinical features of patients with occupational pneumoconiosis (hereinafter referred to as pneumoconiosis) in China. Secondary objectives include: 1) to describe the natural course of pneumoconiosis; 2) to evaluate the prognosis of pneumoconiosis patients; and 3) to assess complications and comorbidities in pneumoconiosis patients.
- Conditions
- Pneumoconiosis
- Medical subject headings
- Pneumoconiosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with pneumoconiosis | This group is composed of patients with pneumoconiosis. | |
| Dust exposure group | This group is composed of patients exposed to dust. | |
| Healthy control group | This group is composed of healthy control subjects. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pulmonary function test
Pulmonary function tests (PFTs) are utilized to assess the severity of the patient's condition, monitor disease progression, guide therapeutic decision-making, and evaluate prognosis.
Measured: 3 years
Secondary outcomes (1)
Number of patients
The researchers used inclusion/exclusion criteria for screening, and collected the demographic information, clinical symptoms and signs, laboratory tests, treatment, survival and other conditions of the patients who agreed to participate in the program and signed the informed consent, and collected biological specimens.
Measured: 6 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2025
- Study start28 May 2021
- Primary completion31 Mar 2026 (estimated)
- Study completion31 May 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PneumoconiosisStudies of the same condition, open and under way.
- More trials run by China-Japan Friendship HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,000 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- China-Japan Friendship Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- KaiLuan General Hospital, The First Affiliated Hospital of Shanxi Medical University, Weifang Respiratory Disease Hospital, Hubei Hospital of Traditional Chinese Medicine, Hunan Prevention and Treatment Institute for Occupational Diseases, China, The first affiliated hospital of chongqing medical and pharmaceutical college, Centers for Disease Control and Prevention, China, Shandong Gold Mining Company Occupational Disease Precention Hospital, Shandong Province Hospital of occupational diseases, The Second Hospital of Heilongjiang Province
- Responsible party
- Principal investigator, Dai Huaping, China-Japan Friendship Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07077382
- Sponsor's protocol ID
- ChinaJapanFH005
- Acronym
- PANDECT
- Status last verified
- Jul 2025
- First submitted
- 23 Jun 2025
- Last updated
- 22 Jul 2025
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pneumoconiosis and Dust Exposure China Cohort
- ClinicalTrials.gov ID
- NCT07077382
- Acronym / sponsor ID
- PANDECT / ChinaJapanFH005
- Conditions
- Pneumoconiosis
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- China-Japan Friendship HospitalUniversity, hospital or other
- Collaborators
- KaiLuan General Hospital, The First Affiliated Hospital of Shanxi Medical University, Weifang Respiratory Disease Hospital, Hubei Hospital of Traditional Chinese Medicine, Hunan Prevention and Treatment Institute for Occupational Diseases, China, The first affiliated hospital of chongqing medical and pharmaceutical college, Centers for Disease Control and Prevention, China, Shandong Gold Mining Company Occupational Disease Precention Hospital, Shandong Province Hospital of occupational diseases, The Second Hospital of Heilongjiang Province
- Study start
- 28 May 2021 (actual)
- Primary completion
- 31 Mar 2026 (estimated)
- Study completion
- 31 May 2030 (estimated)
- First posted
- 22 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to characterize the demographic and clinical features of patients with occupational pneumoconiosis (hereinafter referred to as pneumoconiosis) in China. Secondary objectives include: 1) to describe the natural course of pneumoconiosis; 2) to evaluate the prognosis of pneumoconiosis patients; and 3) to assess complications and comorbidities in pneumoconiosis patients.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Years
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Patients with pneumoconiosis | – | –This group is composed of patients with pneumoconiosis. |
| Dust exposure group | – | –This group is composed of patients exposed to dust. |
| Healthy control group | – | –This group is composed of healthy control subjects. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients were selected during physical examinations or during hospitalization from medical organization.
Key inclusion criteria (1 listed)
- Diagnosed as pneumoconiosis
Key exclusion criteria (2 listed)
- Incomplete occupational history information
- Has participated in any interventional clinical research
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Pulmonary function test
Time frame: 3 years
Pulmonary function tests (PFTs) are utilized to assess the severity of the patient's condition, monitor disease progression, guide therapeutic decision-making, and evaluate prognosis.
1 secondary outcome
Number of patients
Time frame: 6 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2025.
Related trials for Pneumoconiosis
Active, not recruitingEarly Phase 1
FAPI PET for Lung Fibrosis
Interstitial Lung Disease, Idiopathic Interstitial Pneumonias
Not yet recruiting
Feasibility of a Medical-Legal Partnership Model to Connect Coal Miners QuitAid
Tobacco Use Cessation, Tobacco Use Disorder
Enrolling by invitationObservational study
The Edinburgh Lung Fibrosis Molecular Endotyping (ELFMEN) Study
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
RecruitingPhase 3
Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis
Pneumoconiosis
Not yet recruitingPhase 2
Evaluating the Efficacy and Safety of Modified Qing-Zao-Jiu-Fei Decoction on Pneumoconiosis Patients
Pneumoconiosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pneumoconiosis, run by China-Japan Friendship Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pulmonary function test (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2025.